FDA Approval And Improved Coverage Will Unlock Nerve Repair Markets
AN
AnalystConsensusTarget
Not Invested
Consensus Narrative from 7 Analysts
Published
29 May 25
Updated
08 Aug 25
AnalystConsensusTarget's Fair Value
US$24.71
42.7% undervalued intrinsic discount08 Aug
US$14.16
1Y
25.8%7D
3.2%